EUVIMEDEUVIMED entdecken
Multizentrische Studie

Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real‐world study

Dario Graceffa iD, Arianna Zangrilli, Giacomo Caldarola, Viviana Lora, Diego Orsini, Gala Moretta, Gianluca Pagnanelli, Alessia Provini, Cinzia Masini, Mauro Bavetta, Domenico Giordano, Antonio Richetta und 5 weitere

International Journal of Dermatology · 2024

DOI: 10.1111/ijd.17156 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Dario Graceffa und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Dermatology, San Gallicano Dermatological Institute, IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Severity of Illness Index, Quality of Life, Antibodies, Monoclonal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

IL‐23 inhibitors were recently approved for the treatment of skin psoriasis and psoriatic arthritis (PsA). Risankizumab, a humanized monoclonal antibody that specifically binds the p19 subunit of IL‐23, has proven effective on PsA in two randomized controlled trials. To date, only a few real‐world data are available on this topic.

Methods

Our study aimed to prospectively evaluate the effectiveness of risankizumab in patients with PsA in a real‐world setting. For this purpose, both rheumatologic and dermatologic assessments were performed at baseline and after 28–40 weeks of continuous risankizumab administration. Moreover, joint and entheses ultrasound assessment was performed at the mentioned time points. The rheumatologic assessment was carried out by means of the following scores: (i) clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA); (ii) Leeds Enthesitis Index (LEI); (iii) Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and (iii) Bath Ankylosing Spondylitis Functional Index (BASFI). The degree of skin involvement was measured by both the Psoriasis Area and Severity Index (PASI) and Physician Global Assessment (PGA). Quality of life was assessed by the Health Assessment Questionnaire (HAQ) and Dermatology Life Quality Index (DLQI). Ultrasound assessment of joints and entheses was performed on the basis of the EULAR‐OMERACT score.

Results

After treatment, cDAPSA decreased from a mean value of 12.9 ± 7.6 to 7.0 ± 6.1 ( P < 0.001), and the median PD score significantly decreased from baseline (3; range 1–8) to TP1 (1; range 0–7) ( P < 0.001). PASI score also decreased from 8.4 ± 4.9 to 0.3 ± 0.5 ( P < 0.001), and PGA from 3.1 ± 1.0 to 0.4 ± 0.5 ( P < 0.001).

Conclusion

We can conclude that risankizumab led to substantial improvement in both skin and joint involvement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, PsoriaticSeverity of Illness IndexQuality of LifeAntibodies, MonoclonalHumansMaleFemaleMiddle AgedAdultProspective StudiesTreatment OutcomeAgedUltrasonographyInterleukin-23 Subunit p19JointsEnthesopathy

Stichwörter der Autor:innen

arthritispsoriasisrisankizumabultrasound

Substanzen

risankizumabAntibodies, MonoclonalInterleukin-23 Subunit p19

Autor:innen und Institutionen

  • Department of Clinical Dermatology, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
  • Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
  • Dipartimento di Scienze Mediche e Chirurgiche, UOC di Dermatologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
  • Istituto Dermopatico dell'Immacolata, IRCCS, Rome, Italy.
  • UOC Dermatologia, Ospedale San Sebastiano, Frascati (RM), Italy.
  • NESMOS Department, Dermatology Unit, Sant'Andrea Hospital, University of Rome Sapienza, Rome, Italy.

ORCID-Profile: Dario Graceffa

Zitieren

APA

Graceffa, D., Zangrilli, A., Caldarola, G., Lora, V., Orsini, D., Moretta, G., Pagnanelli, G., Provini, A., Masini, C., Bavetta, M., Giordano, D., Richetta, A., Tolino, E., Bianchi, L., Peris, K., Sperati, F., & Bonifati, C. (2024). Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real‐world study. International Journal of Dermatology. https://doi.org/10.1111/ijd.17156

Vancouver

Graceffa D, Zangrilli A, Caldarola G, Lora V, Orsini D, Moretta G, et al. Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real‐world study. International Journal of Dermatology. 2024. doi:10.1111/ijd.17156

BibTeX
@article{Graceffa2024,
  author = {Graceffa, Dario and Zangrilli, Arianna and Caldarola, Giacomo and Lora, Viviana and Orsini, Diego and Moretta, Gala and Pagnanelli, Gianluca and Provini, Alessia and Masini, Cinzia and Bavetta, Mauro and Giordano, Domenico and Richetta, Antonio and Tolino, Ersilla and Bianchi, Luca and Peris, Ketty and Sperati, Francesca and Bonifati, Claudio},
  title = {Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real‐world study},
  journal = {International Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ijd.17156}
}
Kostenlos starten →